ICR urges continued negotiation after NICE rejection of olaparib for early breast cancer 10 Nov 2022 The Institute of Cancer Research, London, is urging NHS-England, NICE and pharmaceutical company AstraZeneca to continue discussions after the disappointing decision not to recommend targeted drug olaparib for women with early-stage, high-risk, inherited breast cancer. Find out more Show/Hide
ICR criticises NICE rejection of olaparib for advanced prostate cancer 06 Sep 2022 The Institute of Cancer Research, London, has expressed disappointment that NICE has confirmed its decision not to recommend olaparib for previously treated, hormone-relapsed metastatic prostate cancer. Find out more Show/Hide
NICE misses golden opportunity to enhance access to innovative cancer drugs 07 Feb 2022 Cancer patients will miss out on exciting new treatments after NICE passed up a golden opportunity to ensure its evaluation methods support approval of the most innovative, potentially game-changing drugs. Find out more Show/Hide
The ICR responds to NICE’s recommendation not to approve abiraterone as first-line treatment for advanced prostate cancer 15 Jul 2021
ASCO 2021: Trial shows benefits of targeted drug against early-stage breast cancer with inherited BRCA mutation 03 Jun 2021
ICR welcomes NICE’s decision to reassess abiraterone as first-line treatment for advanced prostate cancer 29 Oct 2020
Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer 26 Jun 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
ICR responds to NICE approval of palbociclib for treating advanced breast cancer after hormone therapy 28 Nov 2019